Phio Pharmaceuticals Corp (PHIO) - Total Assets
Based on the latest financial reports, Phio Pharmaceuticals Corp (PHIO) holds total assets worth $11.51 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Phio Pharmaceuticals Corp book value and equity for net asset value and shareholders' equity analysis.
Phio Pharmaceuticals Corp - Total Assets Trend (2011–2024)
This chart illustrates how Phio Pharmaceuticals Corp's total assets have evolved over time, based on quarterly financial data.
Phio Pharmaceuticals Corp - Asset Composition Analysis
Current Asset Composition (December 2024)
Phio Pharmaceuticals Corp's total assets of $11.51 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 93.8% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Phio Pharmaceuticals Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see PHIO market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Phio Pharmaceuticals Corp's current assets represent 100.0% of total assets in 2024, an increase from 79.0% in 2011.
- Cash Position: Cash and equivalents constituted 93.8% of total assets in 2024, up from 29.7% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Phio Pharmaceuticals Corp Competitors by Total Assets
Key competitors of Phio Pharmaceuticals Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Phio Pharmaceuticals Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 22.27 | 6.38 | 6.91 |
| Quick Ratio | 22.27 | 6.38 | 6.91 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $10.98 Million | $4.95 Million | $12.97 Million |
Phio Pharmaceuticals Corp - Advanced Valuation Insights
This section examines the relationship between Phio Pharmaceuticals Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.81 |
| Latest Market Cap to Assets Ratio | 2.19 |
| Asset Growth Rate (YoY) | -38.7% |
| Total Assets | $5.74 Million |
| Market Capitalization | $12.59 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Phio Pharmaceuticals Corp's assets at a significant premium (2.19x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Phio Pharmaceuticals Corp's assets decreased by 38.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Phio Pharmaceuticals Corp (2011–2024)
The table below shows the annual total assets of Phio Pharmaceuticals Corp from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $5.74 Million | -38.72% |
| 2023-12-31 | $9.36 Million | -26.92% |
| 2022-12-31 | $12.81 Million | -49.09% |
| 2021-12-31 | $25.17 Million | +59.92% |
| 2020-12-31 | $15.74 Million | +95.78% |
| 2019-12-31 | $8.04 Million | -47.53% |
| 2018-12-31 | $15.32 Million | +273.89% |
| 2017-12-31 | $4.10 Million | -69.41% |
| 2016-12-31 | $13.40 Million | +20.06% |
| 2015-12-31 | $11.16 Million | +21.44% |
| 2014-12-31 | $9.19 Million | -38.49% |
| 2013-12-31 | $14.94 Million | +167.13% |
| 2012-12-31 | $5.59 Million | +230.11% |
| 2011-12-31 | $1.69 Million | -- |
About Phio Pharmaceuticals Corp
Phio Pharmaceuticals Corp., a a clinical stage biotechnology company, engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double posi… Read more